# Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer

> **NCT00411229** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1035 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00411229
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 1035 (ACTUAL)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411229, "Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00411229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*